Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. INVESTOR AGREEMENTInvestor Agreement • June 5th, 2015 • Macrogenics Inc • Pharmaceutical preparations • Delaware
THIS INVESTOR AGREEMENT (this "Agreement") is made as of December 19, 2014, by and among Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation with its principal place of business at 410 George Street, New Brunswick, New Jersey 08901 ("Investor") and MacroGenics, Inc. (the "Company"), a Delaware corporation with its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850.
COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND JANSSEN BIOTECH, INC.Collaboration and License Agreement • June 5th, 2015 • Macrogenics Inc • Pharmaceutical preparations
THIS COLLABORATION AND LICENSE AGREEMENT ("Agreement") is entered into as of December 19, 2014 (the "Execution Date"), by and between JANSSEN BIOTECH, INC., a Pennsylvania corporation, having its principal place of business at 800/850 Ridgeview Drive, Horsham, PA 19044 (hereinafter "Company") and MACROGENICS, INC., a Delaware corporation having its principal place of business at 9640 Medical Center Drive, Rockville, MD 20850 (together with its Affiliates, "MacroGenics"). Company and MacroGenics are sometimes referred to herein individually as a "Party" and collectively as the "Parties".
